Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).
Pediatric Blood and Cancer.
Times cited: 32
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: Results from two randomized, placebo-controlled trials.
British Journal of Haematology.
Times cited: 104
Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: A conceptual model starting with the patient perspective.
Health and Quality of Life Outcomes.
Times cited: 51